Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non–Small Cell Lung Cancer

Published:2018-08 Issue:8 Volume:13 Page:1156-1170
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Fehrenbacher Louis,von Pawel Joachim,Park Keunchil,Rittmeyer Achim,Gandara David R.,Ponce Aix Santiago,Han Ji-Youn,Gadgeel Shirish M.,Hida Toyoaki,Cortinovis Diego L.,Cobo Manuel,Kowalski Dariusz M.,De Marinis Filippo,Gandhi Mayank,Danner Bradford,Matheny Christina,Kowanetz Marcin,He Pei,Felizzi Federico,Patel Hina,Sandler Alan,Ballinger Marcus,Barlesi Fabrice

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference21 articles.

1. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients;Herbst;Nature,2014

2. Molecular pathways: next-generation immunotherapy—inhibiting programmed death-ligand 1 and programmed death-1;Chen;Clin Cancer Res,2012

3. Inhibitory B7-family molecules in the tumour microenvironment;Zou;Nat Rev Immunol,2008

4. Oncology meets immunology: the cancer-immunity cycle;Chen;Immunity,2013

5. B7-DC induced by IL-13 works as a feedback regulator in the effector phase of allergic asthma;Matsumoto;Biochem Biophys Res Commun,2008

Cited by 215 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging Roles of CircRNA-miRNA Networks in Cancer Development and Therapeutic Response;Non-coding RNA Research;2024-09

2. The Association of Immune-Related Adverse Events with the Efficacy of Atezolizumab in Previously Treated Advanced Non-Small-Cell Lung Cancer Patients: A Single-Center Experience;Cancers;2024-08-28

3. Applications of CT-based radiomics for the prediction of immune checkpoint markers and immunotherapeutic outcomes in non-small cell lung cancer;Frontiers in Immunology;2024-08-22

4. Pituitary-adrenal axis dysfunction induced by tislelizumab immunotherapy for non-small cell lung cancer: a case series and literature review;BMC Pulmonary Medicine;2024-07-08

5. Immunotherapy in non-small cell lung cancer: current status, advances and challenges;Minerva Respiratory Medicine;2024-07